Stenotrophomonas maltophilia is an emerging multidrug-resistant (MDR) opportunistic pathogen for which new antibiotic options are urgently needed. We report our clinical experience treating a 19-year-old renal transplant recipient who developed prolonged bacteremia due to metallo-β-lactamase-producing S. maltophilia refractory to conventional treatment. The infection recurred despite a prolonged course of colistimethate sodium (colistin) but resolved with the use of a novel drug combination with clinical efficacy against the patient's S. maltophilia isolate.
CITATION STYLE
Mojica, M. F., Ouellette, C. P., Leber, A., Becknell, M. B., Ardura, M. I., Perez, F., … Shelburne, S. A. (2016). Successful treatment of bloodstream infection due to metallo-β-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient. Antimicrobial Agents and Chemotherapy, 60(9), 5130–5134. https://doi.org/10.1128/AAC.00264-16
Mendeley helps you to discover research relevant for your work.